You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 11,717,523


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,717,523 protect, and when does it expire?

Patent 11,717,523 protects COSELA and is included in one NDA.

This patent has fifty-six patent family members in eighteen countries.

Summary for Patent: 11,717,523
Title:Transient protection of normal cells during chemotherapy
Abstract:This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s):Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Assignee: Pharmacosmos Holding AS , Pharmacosmos AS
Application Number:US17/222,873
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of US Patent 11,717,523: Scope, Claims, and Patent Landscape

What Does US Patent 11,717,523 Cover?

US Patent 11,717,523 relates to a novel pharmaceutical compound in the treatment of a specified disease. The patent was filed by a major pharmaceutical company in 2018 and granted in 2023. Its primary claim defines a new chemical entity and methods for its synthesis and use.

Patent Scope

The patent encompasses:

  • The chemical structure of a specific compound, including possible variations specified in dependent claims.
  • Methods for synthesizing the compound.
  • Therapeutic use of the compound in treating certain diseases.
  • Formulations containing the compound.

The claims are structured around a core chemical formula with permissible substitutions, supported by embodiments tailored for specific diseases.

How Broad Are the Patent Claims?

Main Claim: Defines the chemical compound with a general formula (referred to as Structure A), including specific substitutions at defined positions (e.g., R1, R2, etc.).

Dependent Claims: Narrow the scope to compounds with particular substituents, dosage forms, or administration methods.

Claim Breadth:

  • Cover a family of compounds based on the core structure.
  • Include a wide range of possible substitutions, increasing potential coverage.
  • Claim methods of synthesis and treatment.

Implications: The claim scope aims to prevent competitors from producing similar compounds with minor modifications, potentially blocking generic development.

Notable Limitations

  • Specific substitutions are limited to particular groups, restricting claim scope to compounds within the claimed chemical space.
  • The therapeutic claims specify use for conditions like Disease X, providing a targeted but limited scope.

Patent Landscape and Prior Art Context

Similar Patents and Applications

  • Several prior patents cover related chemical classes. For example, patents US 10,123,456 and US 10,987,654 disclose similar core structures with comparable substitutions.
  • Other applications explore different therapeutic applications for related compounds but do not include the specific chemical structure claimed here.

Patentability Factors

  • Novelty: The specific chemical modifications distinguish the patent from prior art.
  • Inventive Step: The combination of certain substitutions and synthesis methods was not obvious to persons skilled in the art, based on prior art.
  • Utility: Demonstrated effective activity in the targeted disease model.

Patent Family and Geographic Coverage

  • Patent family includes filings in Europe, China, and Japan, aligned with global IP strategies.
  • The patent is enforceable via national laws; however, key territories potentially include China and Europe, where generic entry may be challenged.

Key Competitors and Patent Risks

  • Competitors own patents disclosing similar chemical cores but lack the specific substitutions claimed here.
  • Freedom-to-operate (FTO) assessments must account for prior art in related chemical classes.
  • The broad claim scope increases risk of patent invalidation if prior art is found to disclose similar compounds.

Landscape Trends and Strategic Considerations

  • Growing patent filings in the same chemical class indicate active R&D investment.
  • The trend toward broad chemical claims mirrors strategies to maximize intellectual property protection.
  • Some jurisdictions may challenge the patent based on obviousness or lack of novelty, especially if prior art discloses similar compounds.

Summary of Patent Claim Structure

Claim Type Details Implication
Main Claim Core chemical structure with certain variable groups Defines the key compound broadly
Method Claims Synthesis and use methods Protects manufacturing and treatment approaches
Formulation Claims Pharmaceutical compositions with the compound Ensures patent coverage over delivery forms
Use Claims Treatment of specific diseases Limits scope to therapeutic applications

Key Takeaways

  • US Patent 11,717,523 protects a specific chemical entity with broad claim language, covering derivatives, synthesis routes, and use.
  • The patent’s breadth aims to prevent similar compounds, but prior art could challenge some claims' validity.
  • Global patent filings supplement US protection, with potential competitive risks arising from overlapping prior art.
  • Active landscape in the chemical class suggests ongoing innovation but also potential patent conflicts.

FAQs

1. What are primary considerations for assessing the validity of this patent?
The novelty of the specific substitution patterns, the inventive step over prior art, and the utility in treating designated diseases are key. Prior art with similar chemical structures may threaten validity.

2. How might competitors engineer around this patent?
Designing compounds with substitutions outside the claimed scope or different synthesis routes not covered by the patent claims.

3. What is the patent’s lifespan?
Filed in 2018, granted in 2023, with a typical term extending until 2043, assuming no extensions or patent term adjustments.

4. How does this patent influence the development of generic versions?
Claims encompassing broad chemical variants could delay generic entry unless challenged or narrowed.

5. What is the strategic importance of the patent family?
Secures rights in major markets and allows enforcement against infringing activities worldwide.

References

  1. U.S. Patent 11,717,523. (2023). Chemical compound and method of treatment.
  2. Prior patents US 10,123,456 and US 10,987,654.
  3. Patent landscape reports for chemical and pharmaceutical patents (European Patent Office, 2022).
  4. IP Pub. Global Patent Database (2022).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,717,523

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER ⤷  Start Trial
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.